{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Avelino-Silva VI"],"funding":["NHLBI","NHLBI NIH HHS"],"pagination":["107222"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11569788"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["148"],"pubmed_abstract":["<h4>Background</h4>Exposure to antiretrovirals at or early after HIV acquisition can suppress viral replication and blunt antibody (Ab) responses; a reduced HIV detectability could impact diagnosis and blood donation screening.<h4>Methods</h4>We used three antigen (Ag)/Ab assays and one nucleic acid test (NAT) to analyze samples collected in pre-exposure prophylaxis (PrEP) trials (iPrEx; Partners PrEP) before infection detection by Ab-only rapid diagnostic tests (RDTs), and in early antiretroviral treatment (ART) initiation studies (RV254; SIPP).<h4>Results</h4>Reactivity using NAT and Ag/Ab assays in samples collected up to 8 weeks prior to the first reactive RDT from 251 PrEP trials participants varied between 49-61% for active PrEP users and between 27-37% for placebo users. Among RV254"],"journal":["International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases"],"pubmed_title":["Suppressed HIV antibody responses following exposure to antiretrovirals-evidence from PrEP randomized trials and early antiretroviral treatment initiation studies."],"pmcid":["PMC11569788"],"funding_grant_id":["75N92019D00033","75N92019D00032"],"pubmed_authors":["de Souza M","Grebe E","Lingappa JR","Akapirat S","Conway AL","Vasan S","Norris PJ","Avelino-Silva VI","Kleinman SH","Sacdalan C","NHLBI Recipient Epidemiology and Donor Evaluation Study-IV-Pediatric (REDS-IV-P)","Schmidt M","Defechereux P","Stone M","Custer B","Busch MP","Bakkour S","Mehrotra M","Facente S","Di Germanio C","Wright D","Grant RM","Phanuphak N","Deng X"],"additional_accession":[]},"is_claimable":false,"name":"Suppressed HIV antibody responses following exposure to antiretrovirals-evidence from PrEP randomized trials and early antiretroviral treatment initiation studies.","description":"<h4>Background</h4>Exposure to antiretrovirals at or early after HIV acquisition can suppress viral replication and blunt antibody (Ab) responses; a reduced HIV detectability could impact diagnosis and blood donation screening.<h4>Methods</h4>We used three antigen (Ag)/Ab assays and one nucleic acid test (NAT) to analyze samples collected in pre-exposure prophylaxis (PrEP) trials (iPrEx; Partners PrEP) before infection detection by Ab-only rapid diagnostic tests (RDTs), and in early antiretroviral treatment (ART) initiation studies (RV254; SIPP).<h4>Results</h4>Reactivity using NAT and Ag/Ab assays in samples collected up to 8 weeks prior to the first reactive RDT from 251 PrEP trials participants varied between 49-61% for active PrEP users and between 27-37% for placebo users. Among RV254","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Nov","modification":"2025-04-04T00:48:12.64Z","creation":"2025-04-04T00:48:12.64Z"},"accession":"S-EPMC11569788","cross_references":{"pubmed":["39186969"],"doi":["10.1016/j.ijid.2024.107222"]}}